A unique research peptide, ARA-290 (cibinetide) represents a significant advancement in the field of neuropathy treatment. In Australia, this EPO-derived peptide has garnered increasing attention among medical researchers and specialists treating diabetic neuropathy and small-fiber neuropathy conditions.
While not widely known among general practitioners, ARA-290 has established a solid reputation in specialized neurology circles for its tissue-protective properties without the hematopoietic effects of traditional EPO. Australian research institutions have contributed to the global understanding of its applications, particularly in diabetic patients experiencing chronic pain.
Though still considered experimental by most Australian medical authorities, preliminary clinical evidence has positioned ARA-290 as a promising candidate for neuropathic conditions that have proven resistant to conventional therapies. Patients with severe diabetic neuropathy increasingly inquire about this peptide as an alternative approach when standard treatments fail to provide adequate relief.
- Common Name: Cibinetide
- Goal Slug: neuropathy
- Type Slug: vial-syringe
- Price (AUD): $280-350 per treatment cycle
- WADA Status: :white_check_mark: Permitted
ARA-290 operates through selective binding to the heterodimer of the innate repair receptor (IRR), composed of the EPO receptor and the β common receptor (CD131), without activating the classic EPO receptor homodimer responsible for erythropoiesis.
This selective binding initiates anti-inflammatory and tissue-protective cascades, particularly in nerve tissues experiencing metabolic stress or damage. Think of ARA-290 as a specialized key that unlocks only the “repair door” of cells while ignoring the “blood production door” that full EPO would access.
The peptide acts like a molecular first responder that arrives at damaged nerve sites, reduces the inflammatory “fire,” and activates the cellular repair crews without calling in unnecessary reinforcements.
Steroid Check: ARA-290 is not a steroid and does not exhibit anabolic effects typical of steroid compounds, working instead through cytokine-like signaling pathways.
The Neuropathy Repair Stack. ARA-290 forms the cornerstone of this protocol designed specifically for patients suffering from small-fiber neuropathy, diabetic neuropathy, and other nerve damage conditions.
This stack typically combines ARA-290 with complementary peptides such as BPC-157 for enhanced tissue repair and reduced inflammation, and cerebrolysin to provide neurotrophic support. Additional supplements in this stack often include Alpha Lipoic Acid (600mg daily), Acetyl-L-Carnitine (1000mg daily), and high-dose B vitamins, particularly B1 (thiamine) and B12 (methylcobalamin).
The protocol aims to address neuropathic pain while simultaneously promoting nerve regeneration and improving overall nerve function.
In Australia, ARA-290 occupies a complex regulatory position. As a research peptide, it falls under TGA Schedule 4, requiring prescription by a registered physician.
Medical compounding pharmacies may legally produce ARA-290 for individual patients with specific prescriptions, though availability remains limited to specialized compounders familiar with peptide formulation. The grey market for ARA-290 exists but presents significant risks, as unregulated sources often lack proper quality control and may contain harmful contaminants or incorrect peptide sequences.
Australian customs actively monitors importation of peptides, with penalties for unauthorized importation including seizure of products and possible fines. Patients seeking ARA-290 are strongly advised to consult with physicians specializing in regenerative medicine or neurological conditions who can provide legitimate prescriptions and source the peptide through registered compounding pharmacies.
Dosage: 4mg subcutaneous injection, administered once daily for acute conditions or every other day for chronic conditions.
Cycle: Typical therapeutic protocol involves 28 days of treatment, followed by a 4-week assessment period before determining if additional cycles are warranted. Maximum recommended continuous treatment period is 3 months before requiring a minimum 1-month break.
Administration: ARA-290 is typically supplied as a lyophilized powder requiring reconstitution with bacteriostatic water. After reconstitution, the solution should be stored refrigerated between 2-8°C and used within 14 days.
Injections are administered subcutaneously using a 30G insulin syringe, preferably in the abdominal region, rotating injection sites to prevent localized tissue reactions. Pre-loading insulin syringes for future use is not recommended due to potential peptide degradation.
Introduction
ARA-290 has established a measured reputation in Australia’s therapeutic peptide landscape, attracting attention from specialists in pain management, neuropathy, and inflammatory conditions.
This synthetic peptide derivative of erythropoietin has generated particular interest among Australian endocrinologists and neurologists treating patients with diabetic neuropathy and small-fiber neuropathies where conventional treatments fall short.
Australian researchers have contributed to the global understanding of ARA-290’s tissue-protective properties, with notable work emerging from institutions in Melbourne and Sydney examining its application in metabolic and autoimmune conditions.
While not yet mainstream in Australian clinical practice, ARA-290 represents an emerging class of targeted peptide therapeutics that align with the country’s growing emphasis on precision medicine approaches.
The peptide’s capacity to address tissue damage without stimulating erythropoiesis positions it as a specialized tool for practitioners dealing with complex inflammatory and neuropathic conditions where traditional pathways have been exhausted.
Australian patients with treatment-resistant neuropathic pain increasingly seek information about ARA-290 as part of their therapeutic options. Furthermore, its non-hematopoietic properties enhance its safety profile, making it a promising candidate for long-term management of chronic pain conditions.
Data Profile & Vital Statistics
- Common Name: ARA-290 (Cibinetide)
- Goal Slug: neuropathy
- Type Slug: vial-syringe
- Price (AUD): $485-695 per treatment course
- WADA Status: :white_check_mark: Permitted
- ARA-290 is designed to modulate the immune response in autoimmunity, offering a potential alternative to broad-spectrum immunosuppressants.
Mechanism of Action
ARA-290 interfaces with the NNMT (Nicotinamide N-methyltransferase) pathway indirectly through its modulation of cellular stress responses. When activated by ARA-290, the innate repair receptor reduces oxidative stress markers that typically upregulate NNMT expression in damaged tissues.
By dampening inflammation and improving mitochondrial function, ARA-290 helps maintain NAD+ homeostasis, which NNMT would otherwise deplete during chronic inflammatory states.
This creates a beneficial feedback loop where repair signaling preserves metabolic efficiency. Additionally, 5-Amino-1MQ serves to inhibit NNMT, further supporting metabolic function and energy levels.
Think of ARA-290 as a specialized locksmith that only opens doors to repair workshops, not construction sites. The key fits only certain locks, triggering cleanup crews rather than building crews. These crews specifically target damaged areas while leaving healthy systems untouched.
Steroid Check: ARA-290 has no anabolic androgenic properties whatsoever. It does not affect testosterone levels, does not bind to androgen receptors, and produces no steroid-like side effects.
Its mechanism remains confined to tissue protection and repair through the EPOR-CD131 heterodimer.
Primary Benefits & Applications
ARA-290 (cibinetide) represents a significant advancement in peptide therapeutics focused on tissue restoration rather than growth promotion. Its primary benefits center on three key mechanisms: tissue protection, anti-inflammatory signaling, and nerve function improvement. In Australian clinical settings, ARA-290 has gained particular attention for its application in small-fiber neuropathy treatment, where patients report meaningful reductions in neuropathic pain alongside improved sensory thresholds and quality-of-life metrics.
The peptide’s anti-inflammatory properties make it particularly valuable for conditions characterized by cytokine-driven tissue damage. In sarcoidosis and metabolic disease-associated neuropathies, ARA-290 helps limit ongoing tissue deterioration while supporting functional recovery. Australian researchers have noted promising results in stabilizing inflammatory cascades that typically perpetuate these conditions. Additionally, ARA-290’s role in promoting angiogenesis enhances the delivery of vital nutrients and oxygen to damaged tissues, further supporting recovery.
| Domain | Observed/targeted effect | Example settings |
|---|---|---|
| Neuropathic symptoms | Pain reduction, sensory improvement | Small-fiber neuropathy |
| Inflammatory injury | Cytokine dampening, tissue protection | Sarcoidosis, metabolic disease |
Beyond these primary applications, ARA-290 shows promise for corneal nerve dysfunction and post-ischemic tissue stress. Australian clinical investigations focus on measuring improvements in nerve integrity, symptom relief, and preservation of microvascular function.
Unlike many peptides, ARA-290 is not positioned as an anabolic or hematopoietic agent, making its therapeutic profile distinct. Assessment protocols typically monitor intraepidermal nerve fiber density, autonomic function testing, and inflammatory biomarkers to quantify meaningful clinical improvements.
Synergistic Protocols & Stacks
The Neuropathy Repair Stack provides optimal synergy with ARA-290 by maintaining stable foundational measures while introducing complementary agents. This protocol combines ARA-290’s tissue-protective properties with alpha-lipoic acid (600mg daily) and high-dose B-vitamins (particularly B1, B6, and B12) to support nerve regeneration pathways.
Patients continue with strict glycemic control while incorporating Lion’s Mane mushroom extract (1000mg twice daily) for neurotrophic factor production. Low-dose naltrexone (4.5mg at bedtime) may be added after 4 weeks if inflammatory markers remain elevated.
The protocol emphasizes morning ARA-290 administration followed by gentle nerve-gliding exercises, with evening doses of magnesium threonate (2000mg) to support nerve membrane stability. Clinicians monitor nerve conduction studies at baseline, 6 weeks and 12 weeks, with protocol adjustments based on objective measures rather than symptom reporting alone.
This stack specifically avoids high-dose gabapentinoids which may mask functional improvements in peripheral sensitivity. Additionally, this approach is aligned with the principles of modulating immunity to enhance overall health and recovery.
Buying in Australia: Legal & Market Realities
ARA-290 (cibinetide) is classified as a Schedule 4 (S4) prescription-only medicine in Australia, meaning legal access requires a valid prescription from a registered medical practitioner.
The Therapeutic Goods Administration (TGA) has not approved this peptide for regular therapeutic use, limiting legitimate supply channels to three pathways: participation in authorized clinical trials, through the Special Access Scheme (Category A or B), or via an Authorized Prescriber.
Compounding pharmacies can legally prepare ARA-290 only when a specific patient presents with a valid prescription from a doctor who has determined a clinical need.
These pharmacies must adhere to strict quality control standards and cannot advertise prescription-only compounds to the general public.
The grey market presents significant risks. Online vendors claiming to sell “research chemicals” or “not for human consumption” products circumvent pharmaceutical regulations but offer no quality assurance.
Products may contain incorrect peptide sequences, harmful contaminants, or incorrect dosages. Importing unapproved peptides without proper authorization risks border seizure and potential legal consequences.
Additionally, grey market products lack proper storage validation, potentially compromising stability and efficacy. Semaglutide is approved by the TGA for Type 2 Diabetes and is commonly prescribed off-label for obesity, highlighting the importance of consulting with professionals for safe access.
Patients seeking legitimate access should consult with healthcare providers about appropriate pathways rather than pursuing unregulated supply channels.
Usage Guide: Dosage, Injection, and Cycling
ARA-290 (cibinetide) requires precise dosing and administration. For most therapeutic applications, the recommended dosage is 1-4mg administered via subcutaneous injection, typically once daily or three times weekly. Due to its 2-hour half-life, consistent timing is crucial for maintaining therapeutic effects.
Reconstitution requires bacteriostatic water (0.9% sodium chloride) at a concentration of 1mg/ml. After cleaning the vial tops with an alcohol swab, draw the appropriate amount of diluent using a 1ml insulin syringe, inject it slowly against the vial wall, and gently swirl until fully dissolved. Never shake the vial.
For subcutaneous administration, select rotating injection sites in the abdomen, thigh, or upper arm. Insert a 29-31 gauge insulin needle at a 45-degree angle into pinched skin, inject slowly, and withdraw without massaging the area.
Standard cycling protocols involve 4-6 weeks of daily administration followed by a 2-4 week break. For neuropathy or inflammatory conditions, extended cycles of 8-12 weeks may be appropriate with practitioner monitoring. Treatment efficacy should be assessed after each cycle against predetermined clinical endpoints. Additionally, ensuring adequate high protein intake during treatment can support muscle maintenance and overall health.
Safety Profile: Side Effects & Common Questions
ARA-290 (cibinetide) generally presents a favorable safety profile in clinical research settings, though considerations center on short-lived injection-site reactions and mild systemic symptoms. Users should be aware of the limited long-term safety data outside specific studied populations.
Commonly reported adverse events are typically mild, including transient erythema, tenderness, or pruritus at the injection site, as well as occasional headache, nausea, fatigue, or dizziness in some individuals. Clinical studies have demonstrated no erythropoietic stimulation (red blood cell production) at the doses typically studied. Additionally, ARA-290’s ability to target the Innate Repair Receptor (IRR) may contribute to its unique mechanism in pain management.
Healthcare practitioners recommend caution in patients with unstable cardiovascular disease, active malignancy, pregnancy, or severe renal/hepatic impairment due to insufficient evidence in these populations. Patients are advised to discontinue ARA-290 and seek immediate medical evaluation if experiencing signs of significant adverse reactions such as rash, wheezing, facial/throat swelling, chest pain, or persistent fever.
| Common question | Practical answer |
|---|---|
| Can it raise hematocrit like EPO? | Trials suggest it does not. |
| How long do side effects last? | Often hours to a day. |
